Effect of burning alfalfa stubble for insect pest control on seed yield

Burning alfalfa (Medicago sativa (L.) stubble in the spring has been shown to be effective in reducing some insect pest populations. A study was conducted to detennine the long-tenn effect of this practice on seed yield. Plots were established at Lethbridge, Alberta, and burned in the spring or fall at various heights of plant growth from 1983 to 1989, with one half of each plot treated annually with insecticides when the pest insects were in their most vulnerable stage. Yields from burned treatments were not significantly different from unburned ones for the years 1983 to 1986, and 1988. In 1987, treatments burned in the fall had significantly higher yields than other treatments. Burning at 15-20 cm of growth significantly reduced yield compared to burning before spring growth. In 1989, yields from plots burned at 15-20 cm of growth were significantly lower than those burned every fall or spring. Insecticide treated plots had significantly higher yields in all years except 1983. Burning in the fall, or in the spring before growth, increased gross economic returns, but insecticide treatment gave the highest returns

The effect of pulse crop rotation and controlled-release urea on the N accumulation and end-use quality of CWRS wheat

Non-Peer ReviewedSpring wheat was grown at Carman in 2000 and 2001, and at Brandon, MB, in 2001, on field pea and flax stubble at three rates of N (0, 30, and 90 kg N ha-1) supplied as ammonium nitrate (AN) or controlled release urea (CRU), a polyurethane-coated urea. Wheat was grown in 2000 and 2001 at Swift Current, SK, on field pea and durum stubble at three rates of urea N (34, 50, and 78 kg N ha-1) based on soil test recommendations. Wheat grown on field pea stubble (P-W) had higher protein content (PC) than wheat grown on flax/durum stubble (F-W) at four of the five sites evaluated. Contrary to expectations, post-anthesis apparent net mineralized N and proportion of total N uptake were higher for F-W compared to P-W at the Carman 2000 and Brandon 2001 sites. Differences between fertilizer N sources were minor. Breadmaking quality of the wheat end-use quality was also assessed. At the same flour protein content (FPC), P-W had a shorter Mixograph dough development time, work input-to-peak, dough strength index, and breakdown resistance, and also tended to be more extensible than F-W

Assessment of sweep net and suction sampling for evaluating pest insect populations in hay alfalfa

Insect populations in alfalfa grown for hay can be sampled using several methods. However, in a pest management program a relatively easy, quick, and reliable method of sampling is essential for making effective pest control decisions. A study was conducted to determine if two different sampling methods, sweepnet sampling and suction sampling, led to similar pest control decisions. Differences between sweepnet and D-Vac insect population estimates varied over sampling dates and years and were dependent on the insect species, their developmental stages, and abiotic factors. Our results indicate that, for many sampling dates, decisions on control of some pest insects would be similar for the two sampling methods.Keywords: Insecta; Medicago sativa; alfalfa weevil; pea aph

Complex Propagation Patterns Characterize Human Cortical Activity during Slow-Wave Sleep

Cortical electrical activity during nonrapid eye movement (non-REM) sleep is dominated by slow-wave activity (SWA). At larger spatial scales (similar to 2-30 cm), investigated by scalp EEG recordings, SWA has been shown to propagate globally over wide cortical regions as traveling waves, which has been proposed to serve as a temporal framework for neural plasticity. However, whether SWA dynamics at finer spatial scales also reflects the orderly propagation has not previously been investigated in humans. To reveal the local, finer spatial scale (similar to 1-6 cm) patterns of SWA propagation during non-REM sleep, electrocorticographic (ECoG) recordings were conducted from subdurally implanted electrode grids and a nonlinear correlation technique [mutual information (MI)] was implemented. MI analysis revealed spatial maps of correlations between cortical areas demonstrating SWA propagation directions, speed, and association strength. Highest correlations, indicating significant coupling, were detected during the initial positive-going deflection of slow waves. SWA propagated predominantly between adjacent cortical areas, albeit spatial noncontinuities were also frequently observed. MI analysis further uncovered significant convergence and divergence patterns. Areas receiving the most convergent activity were similar to those with high divergence rate, while reciprocal and circular propagation of SWA was also frequent. We hypothesize that SWA is characterized by distinct attributes depending on the spatial scale observed. At larger spatial scales, the orderly SWA propagation dominates; at the finer scale of the ECoG recordings, non-REM sleep is characterized by complex SWA propagation patterns

Evolution of Integrated Crop-Livestock Production Systems

Key points 1. Many factors contribute to changes in the crop-livestock systems, but no logical end-point in the evolution process exists. 2. While benefits of integrated crop-livestock systems over specialised crop and livestock systems are well documented, there has been a move to specialised crop and livestock production. 3. Sustainability issues (manure nutrient concentration, soil quality maintenance, salinity, herbicide resistance, economic instability) have created a renewed interest in integrated crop-livestock systems. 4. Farmer adaptability is as an important link in the evolution between ‘states of integration’

Evolution of Integrated Crop-Livestock Production Systems

Many factors contribute to changes in the crop-livestock systems, but no logical end-point in the evolution process exists. While benefits of integrated crop-livestock systems over specialised crop and livestock systems are well documented, there has been a move to specialised crop and livestock production. Sustainability issues (manure nutrient concentration, soil quality maintenance, salinity, herbicide resistance, economic instability) have created a renewed interest in integrated crop-livestock systems. Farmer adaptability is as an important link in the evolution between ‘states of integration’

Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity.

BACKGROUND:Pediatric high-grade gliomas (pHGGs) are facing a very dismal prognosis and representative pre-clinical models are needed for new treatment strategies. Here, we examined the relevance of collecting functional, genomic, and metabolomics data to validate patient-derived models in a hypoxic microenvironment. METHODS:From our biobank of pediatric brain tumor-derived models, we selected 11 pHGGs driven by the histone H3.3K28M mutation. We compared the features of four patient tumors to their paired cell lines and mouse xenografts using NGS (next generation sequencing), aCGH (array comparative genomic hybridization), RNA sequencing, WES (whole exome sequencing), immunocytochemistry, and HRMAS (high resolution magic angle spinning) spectroscopy. We developed a multicellular in vitro model of cell migration to mimic the brain hypoxic microenvironment. The live cell technology Incucyte© was used to assess drug responsiveness in variable oxygen conditions. RESULTS:The concurrent 2D and 3D cultures generated from the same tumor sample exhibited divergent but complementary features, recreating the patient intra-tumor complexity. Genomic and metabolomic data described the metabolic changes during pHGG progression and supported hypoxia as an important key to preserve the tumor metabolism in vitro and cell dissemination present in patients. The neurosphere features preserved tumor development and sensitivity to treatment. CONCLUSION:We proposed a novel multistep work for the development and validation of patient-derived models, considering the immature and differentiated content and the tumor microenvironment of pHGGs

Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD)

Constitutional mismatch repair deficiency (CMMRD) syndrome is a distinct childhood cancer predisposition syndrome that results from biallelic germline mutations in one of the four MMR genes, MLH1, MSH2, MSH6 or PMS2. The tumour spectrum is very broad, including mainly haematological, brain and intestinal tract tumours. Patients show a variety of non-malignant features that are indicative of CMMRD. However, currently no criteria that should entail diagnostic evaluation of CMMRD exist. We present a three-point scoring system for the suspected diagnosis CMMRD in a paediatric/young adult cancer patient. Tumours highly specific for CMMRD syndrome are assigned three points, malignancies overrepresented in CMMRD two points and all other malignancies one point. According to their specificity for CMMRD and their frequency in the general population, additional features are weighted with 1-2 points. They include multiple hyperpigmented and hypopigmented skin areas, brain malformations, pilomatricomas, a second childhood malignancy, a Lynch syndrome (LS)-associated tumour in a relative and parental consanguinity. According to the scoring system, CMMRD should be suspected in any cancer patient who reaches a minimum of three points by adding the points of the malignancy and the additional features. The diagnostic steps to confirm or refute the suspected diagnosis are outlined. We expect that application of the suggested strategy for CMMRD diagnosis will increase the number of patients being identified at the time when they develop their first tumour. This will allow adjustment of the treatment modalities, offering surveillance strategies for second malignancies and appropriate counselling of the entire family

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Background: Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 dose and antitumour activity of lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma. // Methods: This multicentre, open-label, multicohort, phase 1/2 trial was done at 17 hospitals in six countries. Eligible patients were aged 2–25 years, had relapsed or refractory osteosarcoma, measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1, Lansky play–performance score or Karnofsky performance score of 50% or higher, up to one previous VEGF or VEGF receptor-targeted therapy, and a life expectancy of at least 3 months. This study includes a combination dose-finding phase 1 part (cohort 3A) and a phase 2 combination expansion in patients with osteosarcoma (cohort 3B). Lenvatinib was administered orally at a starting dose of 11 mg/m2 per day, capped at 24 mg per day, and etoposide (100 mg/m2 per day) plus ifosfamide (3000 mg/m2 per day) were administered intravenously on days 1–3 of each 21-day cycle for a maximum of five cycles. Lenvatinib monotherapy continued after these five cycles until disease progression, toxic effects, or patient choice to discontinue. The phase 1 primary endpoint was to determine the recommended phase 2 dose by evaluating dose-limiting toxicity and the phase 2 primary endpoint was progression-free survival at 4 months. Progression-free survival was measured in the full analysis set, which included all patients enrolled for efficacy outcomes; safety was assessed in all patients who received any study drug. This study is registered with ClinicalTrials.gov, NCT02432274. // Findings: 30 patients were screened for enrolment into cohort 3A between May 9, 2016, and June 3, 2019, and 22 patients for enrolment into cohort 3B between Sept 13, 2018, and July 18, 2019. Eight patients from cohort 3A and two from cohort 3B were ineligible for enrolment in the study. In phase 1, dose-limiting toxicities were observed in three patients (one in the lenvatinib 11 mg/m2 combination group and two in the 14 mg/m2 combination group) and the recommended phase 2 dose was determined as lenvatinib 14 mg/m2 per day (with daily dose cap of 24 mg) and etoposide 100 mg/m2 per day plus ifosfamide 3000 mg/m2 per day administered intravenously on days 1–3 of each 21-day cycle for a maximum of five cycles. 35 patients from phase 1 (cohort 3A; n=15) and phase 2 (cohort 3B; n=20) were treated at the recommended phase 2 dose and their results were pooled. Progression-free survival at 4 months was 51% (95% CI 34–69) in 18 of 35 patients per the binomial estimate. The most common grade 3–4 treatment-emergent adverse events were neutropenia (27 [77%] of 35), thrombocytopenia (25 [71%]), anaemia (19 [54%]), and decreased white blood cell count (19 [54%]). 26 [74%] of 35 patients had serious treatment-emergent adverse events and no treatment-related deaths occurred. // Interpretation: Lenvatinib with etoposide plus ifosfamide shows promising antitumour activity with no new safety signals in patients with refractory and relapsed osteosarcoma. These findings warrant further investigation in an ongoing randomised phase 2 study (NCT04154189)